# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products...
Wedbush analyst Scott Devitt reiterates Tripadvisor (NASDAQ:TRIP) with a Neutral and maintains $21 price target.
Barclays analyst Ross Sandler maintains Tripadvisor (NASDAQ:TRIP) with a Underweight and lowers the price target from $20 to...
Wedbush analyst Scott Devitt maintains Tripadvisor (NASDAQ:TRIP) with a Neutral and lowers the price target from $30 to $21.
JP Morgan analyst Doug Anmuth maintains Tripadvisor (NASDAQ:TRIP) with a Underweight and lowers the price target from $25 to...
UBS analyst Lloyd Walmsley maintains Tripadvisor (NASDAQ:TRIP) with a Neutral and lowers the price target from $27 to $20.
BMO Capital analyst Brian Pitz maintains Tripadvisor (NASDAQ:TRIP) with a Market Perform and lowers the price target from $2...